(Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials

@article{Wang2012BortezomibPL,
  title={(Bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials},
  author={Anyou Wang and Qiaohong Duan and Xin Liu and Kaiyang Ding and Yongsheng Han and Weibo Zhu and Xiaoyan Cai and Jingsheng Wu and Zi-min Sun},
  journal={Annals of Hematology},
  year={2012},
  volume={91},
  pages={1779-1784}
}
The aim of the study was to perform a meta-analysis of the efficacy and safety of (bortezomib plus lenalidomide/thalidomide)- vs (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma. We searched electronic and printed sources for relevant articles published. Inclusion criteria was as follows: randomized controlled trials (RCT) of (bortezomib plus lenalidomide/thalidomide) vs (bortezomib or lenalidomide/thalidomide)-containing… CONTINUE READING